Grocery store operator The Kroger Company plans to sell its specialty pharmacy business to CarelonRx, a subsidiary of Elevance Health.Kroger has entered into a definitive agreement for the sale, the company said in a Monday (March 18) press release. Subject to customary closing conditions and regulatory approvals, the sale is expected to close in the second half.“As part of our regular review of assets, it became clear that our strong specialty pharmacy business unit will better meet its full potential outs ...

Elevance Health, Inc. (ELV) is strategically poised for growth, driven by increasing memberships in individual commercial risk-based businesses and Blue Card businesses. Improving performance in the Carelon Services business is a significant tailwind for the company.Elevance, with a market capitalization of $118.6 billion, is a major health benefits company in the United States. Due to solid prospects, this currently Zacks Rank #2 (Buy) stock is worth investing in at the moment. In this analysis, we'll expl ...

Elevance Health (ELV) closed the latest trading day at $510.57, indicating a +0.21% change from the previous session's end. The stock exceeded the S&P 500, which registered a loss of 0.29% for the day. Meanwhile, the Dow experienced a drop of 0.35%, and the technology-dominated Nasdaq saw a decrease of 0.3%.The health insurer's stock has climbed by 0.67% in the past month, falling short of the Medical sector's gain of 3.72% and the S&P 500's gain of 4.42%.The investment community will be closely monitoring ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about Elevance Health (ELV) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Elevance Health currently has an average brokerage recomm ...

公司收购 - Elevance Health, Inc. 完成了对 Paragon Healthcare, Inc. 的收购，以提升其在多地点输液服务和专科药房方面的能力[1] - 通过将 Paragon Healthcare 整合到其 CarelonRx 药房服务部门，ELV有望降低护理成本，为患者提供更多输液药物选择[3] Paragon Healthcare 网络 - Paragon Healthcare 在八个州拥有广泛的门诊输液中心和家庭输液药房网络，为超过35,000名患者提供生命拯救和生命赋予疗法[5]

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) today announced the closing of its acquisition of Paragon Healthcare, Inc., a company specializing in life-saving and life-giving infusible and injectable therapies. Paragon Healthcare provides infusion services to patients through its omnichannel model of ambulatory infusion centers, home infusion pharmacies, and other specialty pharmacy services. The company, headquartered in Plano, Texas, currently serves more than 35,000 patients at over 40 a ...

nortonrsx/iStock via Getty Images Elevance Health, Inc. (NYSE:ELV) reported strong financial growth in Q4 and full year 2023 with the increase in revenues and earnings per share. This growth was driven by the uptick in premium and product revenues. The company also showed growth in net income in 2023, despite the increase in total expenses. This article presents the financial metrics of Elevance Health, strategic contribution of different segments and technical analysis based on the historical trends. I ...

估值比较 - Elevance Health (ELV) 和 GoodRx Holdings, Inc. (GDRX) 都拥有Zacks Rank 2 (买入) [3] - ELV 的前瞻市盈率为13.42，而GDRX的前瞻市盈率为22.86 [6] - ELV 的P/B比率为2.97，而GDRX的P/B比率为4.06 [7] - 基于众多估值指标，ELV的价值评级为A，而GDRX的价值评级为D [7] - 根据这些估值数据，公司认为ELV目前是更具价值的选择 [8]

财务表现 - Elevance Health第四季度2023年调整后每股收益为5.62美元，超过Zacks Consensus Estimate 1.3%[3] - 营业收入同比增长7%，达到约425亿美元，超过共识预期1.5%[4] - 预计2024年调整后每股收益将超过37.10美元，GAAP收益预计将超过34.29美元[6] 业务表现 - 高商业健康福利业务保费和Carelon服务业务表现提升，但高费用水平部分抵消了上涨[5] - 预计2024年营业收入将从2023年的170.2亿美元增长至平稳至低个位数增长，保费收入预计将保持在142.9亿美元水平[7] - Health Benefits部门第四季度营业收入为365亿美元，同比增长4.3%，操作利润同比下降2.3%[13] - Carelon部门第四季度营业收入同比增长14.1%，操作利润同比增长15.2%[14] 资产状况 - 公司第四季度现金及现金等价物为65亿美元，总资产为108.9亿美元，长期债务为23.2亿美元[17] - 公司在第四季度回购了价值9.29亿美元的股票，截至2023年12月31日，剩余约42亿美元的回购授权[20] 现金流 - 预计2024年净投资收入将为19亿美元，利息支出预计为11亿美元，运营现金流预计将超过2023年的81亿美元水平[8] - Elevance Health在2023年产生了81亿美元的经营现金流，略有下降[19]

股价表现 - Elevance Health (ELV) 最新收盘价为 $512.17，较前一交易日上涨了 +0.55% [1] 财务表现 - 分析师预计 Elevance Health 将在即将公布的财报中每股盈利为 $10.60，同比增长 12.05%，预计营收为 $42.7 亿美元，同比增长 1.92% [3] 股票评级 - Elevance Health 目前的 Zacks Rank 为 2 (买入)，过去一个月的 Zacks Consensus EPS 估计上调了 0.24% [7] 估值比较 - Elevance Health 目前的 Forward P/E 比率为 13.73，低于行业平均值 20.27 [8]